US Bancorp DE reduced its holdings in Davita Inc (NYSE:DVA) by 14.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 8,254 shares of the company’s stock after selling 1,353 shares during the quarter. US Bancorp DE’s holdings in Davita were worth $544,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Boston Partners boosted its stake in shares of Davita by 39.7% in the 1st quarter. Boston Partners now owns 2,036,058 shares of the company’s stock valued at $134,258,000 after purchasing an additional 578,242 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Davita by 239.9% in the 4th quarter. Millennium Management LLC now owns 2,024,308 shares of the company’s stock valued at $146,256,000 after purchasing an additional 1,428,810 shares during the last quarter. OppenheimerFunds Inc. boosted its stake in Davita by 5,292.6% during the fourth quarter. OppenheimerFunds Inc. now owns 1,873,918 shares of the company’s stock worth $135,391,000 after acquiring an additional 1,839,168 shares in the last quarter. Geode Capital Management LLC boosted its stake in Davita by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,609,652 shares of the company’s stock worth $116,051,000 after acquiring an additional 16,017 shares in the last quarter. Finally, Bridger Management LLC bought a new position in Davita during the fourth quarter worth $52,339,000. Hedge funds and other institutional investors own 87.71% of the company’s stock.
Davita traded down $0.11, reaching $70.86, on Thursday, Marketbeat.com reports. 10,728 shares of the company’s stock were exchanged, compared to its average volume of 1,550,127. The company has a quick ratio of 2.90, a current ratio of 2.94 and a debt-to-equity ratio of 1.94. The firm has a market capitalization of $12.58 billion, a PE ratio of 21.31, a P/E/G ratio of 1.05 and a beta of 1.10. Davita Inc has a 52 week low of $52.51 and a 52 week high of $80.71.
Davita (NYSE:DVA) last issued its earnings results on Thursday, May 3rd. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.13. Davita had a net margin of 2.94% and a return on equity of 13.84%. The firm had revenue of $2.85 billion during the quarter, compared to analyst estimates of $2.79 billion. During the same quarter last year, the business earned $0.79 earnings per share. The company’s quarterly revenue was up 8.3% on a year-over-year basis. analysts anticipate that Davita Inc will post 4.1 earnings per share for the current fiscal year.
In other Davita news, Director William L. Roper sold 1,505 shares of Davita stock in a transaction that occurred on Tuesday, May 22nd. The shares were sold at an average price of $68.22, for a total transaction of $102,671.10. Following the transaction, the director now directly owns 46,733 shares of the company’s stock, valued at $3,188,125.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Pamela M. Arway sold 1,264 shares of Davita stock in a transaction that occurred on Thursday, June 7th. The stock was sold at an average price of $68.76, for a total transaction of $86,912.64. Following the transaction, the director now directly owns 39,235 shares in the company, valued at $2,697,798.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,107 shares of company stock valued at $211,976. 0.95% of the stock is currently owned by company insiders.
A number of research firms have weighed in on DVA. SunTrust Banks reaffirmed a “hold” rating and issued a $80.00 price objective on shares of Davita in a research note on Wednesday, February 14th. William Blair reaffirmed a “buy” rating on shares of Davita in a research note on Wednesday, June 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Davita presently has a consensus rating of “Buy” and an average target price of $81.22.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Receive News & Ratings for Davita Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Davita and related companies with MarketBeat.com’s FREE daily email newsletter.